Tactiva Plans Cancer Trials For Next-Generation Cell Therapy
Emerging company profile: founded in early 2016, Tactiva Therapeutics licensed its adoptive cell therapy technology from Roswell Park Cancer Institute. CEO Matthew E. Colpoys told Scrip about the company's plans to raise funds to push its immunotherapy into clinical trials in five tumor types.
You may also be interested in...
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.